How many FDA approved circRNA vaccine are there?

Introduction to circRNA Vaccines 

Circular RNAs (circRNAs) are a unique class of RNA molecules that, unlike their linear counterparts, form covalently closed loops. This closed-loop structure results from a process called backsplicing, where a downstream 3′ splice site is joined to an upstream 5′ splice site. Because they lack free 5′ and 3′ ends, circRNAs are inherently resistant to exonuclease-mediated degradation. This structural stability fosters prolonged protein expression when they encode open reading frames (ORFs) that are translated via internal ribosome entry sites (IRESs) or N⁶-methyladenosine (m⁶A) modification-dependent mechanisms. In the vaccine context, circRNA technology aims to overcome the challenges faced by traditional linear mRNA vaccines, particularly by providing enhanced durability and stability for antigen production in vivo. 

Advantages over Traditional Vaccines 
CircRNA vaccines offer several theoretical advantages over conventional vaccine platforms, including: 
- Enhanced Stability: The circular structure protects the RNA from exonuclease degradation, potentially allowing for longer antigen expression and a more durable immune response. 
- Simpler Storage Requirements: With increased inherent stability, circRNA vaccines might require less stringent cold-chain logistics compared to traditional mRNA vaccines, which need ultracold storage conditions. 
- Efficient Protein Expression: CircRNAs can incorporate IRES elements and other translation-enhancing sequences to drive efficient protein production, even at lower doses. 
- Potential for Broader Application: Beyond infectious diseases, circRNA technology also shows promise in cancer vaccines, protein replacement therapies, and other therapeutic areas. 

Regulatory Approval Process 
FDA Approval Criteria for Vaccines 
The United States Food and Drug Administration (FDA) rigorously assesses vaccine candidates based on multiple criteria during the clinical development process. These include: 
- Preclinical Safety and Efficacy: Vaccines must demonstrate robust immunogenicity and a favorable safety profile in animal models before transitioning into human trials. 
- Clinical Trial Data: The candidate must go through phased clinical trials (Phase I for safety, Phase II for dosage and further safety, and Phase III for efficacy and large-scale safety) with statistically significant and reproducible results. 
- Manufacturing Quality: Compliance with Good Manufacturing Practice (GMP) is essential. The manufacturing process must ensure consistency, purity, and potency across production batches. 
- Risk–Benefit Analysis: The FDA undertakes a comprehensive review of the vaccine’s benefits versus potential risks, considering the disease burden and the availability of alternative interventions. 

Specific Requirements for circRNA Vaccines 
For any novel vaccine platform, including circRNA vaccines, additional challenges must be addressed to meet FDA approval: 
- Demonstration of Long-Term Stability: As circRNA vaccines are designed based on unique circular molecules, extensive data must confirm that their increased stability translates into sustained antigen expression without unforeseen degradation products. 
- Proof of Translatability: Since circRNAs lack a 5′ cap and poly(A) tail, it is crucial to demonstrate that added elements (e.g., IRES sequences or m⁶A modifications) consistently drive robust translation of the encoded antigen in vivo. 
- Comparative Immunogenicity: The immune responses generated by circRNA vaccines must be at least comparable to those produced by the more established mRNA vaccines, which have already garnered FDA approval for several indications. 
- Manufacturing Scalability and Quality Control: Novel production methods specific to circRNAs—such as enzymatic or ribozyme-mediated circularization—must not only produce a high yield but also maintain stringent quality standards under GMP conditions. 

Current Status of circRNA Vaccines 
Approved circRNA Vaccines 
To date, there are zero FDA-approved circRNA vaccines. Although circRNA vaccines have been actively researched and have shown promising preclinical and early clinical results, none have completed the entire regulatory pathway required for FDA approval. The vaccines that currently hold FDA approval for COVID-19, for instance, are based on mRNA, adenoviral vectors, inactivated virus, or protein subunits rather than circRNA technology. This reflects both the novelty of the circRNA platform and the fact that its clinical translation is still in the preliminary stages compared to the more mature mRNA vaccine field. 

Clinical Trials and Pipeline 
CircRNA vaccines remain in the research and development phase, with many studies demonstrating their potential advantages in preclinical settings. In experiments involving animal models, circRNA vaccines have elicited robust humoral and cellular immune responses and have outperformed some of their linear counterparts in terms of durability and expression levels. Furthermore, several research groups and biotech companies are exploring circRNA candidates for applications against infectious diseases and cancer, as documented in various patents and review articles. However, as none have yet advanced to phases that would culminate in FDA approval, the circRNA vaccine pipeline is primarily at the preclinical stage, with preparations for early-phase clinical trials being discussed or planned rather than finalized and approved. 

Future Prospects and Challenges 
Potential Challenges in Development 
Several challenges must be addressed for circRNA vaccines to progress toward clinical use and FDA approval: 
- Translational Efficiency: Although circRNAs have an advantage regarding stability, ensuring that the encoded antigen is produced in sufficient quantities and with consistent kinetics is a key hurdle. Optimization of IRES elements and tandem regulatory sequences is ongoing to maximize translation efficiency. 
- Manufacturing Scale-Up: Scaling up circRNA production while ensuring quality, purity, and reproducibility under GMP conditions is technically challenging. The circularization process itself—whether using enzymatic ligation or ribozymes—requires standardization to avoid heterogeneous products or unwanted by-products. 
- Safety Profile: While the inherent stability of circRNAs is an advantage, there is a need to thoroughly evaluate their long-term safety, including potential immunogenicity of the circular junctions or aberrant immune responses, which may differ from linear mRNA vaccines. 
- Delivery Systems: Similar to mRNA vaccines, circRNA candidates require efficient delivery systems (e.g., lipid nanoparticles) to ensure that the RNA reaches the target cells in vivo. Optimization of these systems specifically for circRNAs will be critical, as their physical and chemical properties may differ from those of linear mRNAs. 
- Regulatory Pathway Uncertainties: As a novel vaccine platform, circRNA vaccines currently do not have an established regulatory framework. Extensive preclinical and early clinical data will need to be generated to inform FDA guidance on their evaluation, which could prolong the development timeline. 

Future Research Directions 
Given the novelty of circRNA vaccine platforms and their promising advantages, future research is focusing on several key areas: 
- Optimization of Expression Constructs: Research is needed to refine the design of circRNA constructs—improving IRES elements, exploring different circularization methods, and incorporating modifications like m⁶A to further boost protein translation. 
- Advanced Delivery Technologies: Significant efforts are underway to develop more efficient delivery vehicles optimized for circRNA molecules. These include reformulated lipid nanoparticles and alternative non-viral vector systems that could enhance targeted delivery and reduce off-target effects. 
- Expanded Preclinical Studies: More comprehensive studies in various animal models will solidify our understanding of the immunogenicity, safety, and efficacy of circRNA vaccines. Comparative studies with existing mRNA vaccines will be particularly important to validate the purported benefits of circRNA technology. 
- Clinical Trial Initiatives: Preparing for Phase I and Phase II trials, researchers are focusing on establishing robust safety and efficacy profiles. Early human studies will help identify any potential issues specific to the circular RNA platform and pave the way for larger, pivotal trials. 
- Regulatory Engagement: As the technology matures, engaging with regulatory bodies such as the FDA to establish guidelines for circRNA vaccine evaluation will be critical. This could help streamline the development process by reducing uncertainties and establishing specific criteria tailored to the unique aspects of circRNA vaccines. 

Conclusion 
In summary, circRNA vaccines are an innovative and promising platform that leverages the enhanced stability and potentially efficient antigen expression of circular RNA molecules. Their mechanism—based on backsplicing and IRES-mediated translation—provides notable advantages over traditional linear mRNA vaccines, especially in terms of durability and possibly relaxed cold-storage requirements. However, the regulatory approval process for vaccines, particularly by the FDA, is very rigorous. It requires extensive evidence of safety, immunogenicity, and manufacturing quality through well-defined clinical trials. 

Presently, there are zero FDA-approved circRNA vaccines. All current FDA-approved vaccines, including those for SARS‑CoV‑2, are based on mRNA, viral vectors, inactivated viruses, or protein subunits. CircRNA vaccines remain in the preclinical stage or early stages of clinical development, with many research groups actively working on overcoming challenges related to translation efficiency, large-scale manufacturing, delivery systems, and regulatory standardization. 

From a general perspective, while circRNA technology holds significant promise due to its theoretical advantages over conventional vaccine platforms, the pathway to FDA approval is still under development. Specifically, the accumulation of robust preclinical data and the design of early-phase clinical trials will be paramount in moving circRNA vaccines from the bench to the bedside. In a specific context, the current evidence and regulatory documentation indicate that no circRNA vaccines have yet reached the phase where FDA approval is granted. Looking to the future, research directed at optimizing circRNA constructs, enhancing delivery systems, and systematically addressing safety and efficacy will be essential. Only then can the unique advantages of circRNA vaccines be fully realized in clinical settings. 

In conclusion, based on the reliable and structured information from sources such as synapse and others, there are currently no FDA-approved circRNA vaccines. Further research and development are necessary to bridge the gap between promising laboratory results and clinical application, ensuring that this innovative vaccine platform can eventually meet all regulatory requirements and offer a viable alternative to existing vaccination technologies.

Discover Eureka LS: AI Agents Built for Biopharma Efficiency

Stop wasting time on biopharma busywork. Meet Eureka LS - your AI agent squad for drug discovery.

▶ See how 50+ research teams saved 300+ hours/month

From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.